lm-299 merck news - Search News

Merck to buy rights to Chinese cancer drug

Reuters on MSN · 1d

Merck signs up to $3.3 billion cancer drug deal with China-based LaNova

Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months after a similar therapy from Summit Therapeutics outperformed its blockbuster Keytruda in a late-stage trial in the country.

Seeking Alpha · 1d

Merck to buy rights to Chinese cancer drug for up to $3.3B

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate called LM-299 from LaNova. Read more here.

Merck strikes $3.3B licensing deal for Chinese cancer drug

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

1d

Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held ...

21h

Merck enters exclusive global license for LM-299

Merck (MRK) and LaNova Medicines, a privately held clinical-stage biotechnology company, announced that Merck has entered into an exclusive ...

Investor's Business Daily on MSN15h

Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

FierceBiotech1d

Merck pays $588M for bispecific to defend Keytruda’s kingdom from emerging threat

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

1d

Merck Expands Oncology Pipeline By Securing License For LaNova Medicines' LM-299

Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results